Technology
Health
Biotechnology

Myriad Genetics

$25.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.15 (9.27%) Today
-$0.15 (-0.59%) As of 5:40 PM EDT after-hours

Why Robinhood?

You can buy or sell MYGN and other stocks, options, ETFs, and crypto commission-free!

About MYGN

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through Diagnostics and Other segments. Read More The Diagnostics segment engages in the provision of testing and collaborative development of testing that is designed to asses a risk of developing a disease later in life of an individual. The Other segmeng provides products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.

Employees
2,600
Headquarters
Salt Lake City, Utah
Founded
1991
Market Cap
1.86B
Price-Earnings Ratio
427.49
Dividend Yield
0.00
Average Volume
2.50M
High Today
$25.52
Low Today
$23.26
Open Price
$23.86
Volume
2.01M
52 Week High
$50.44
52 Week Low
$22.07

Collections

Technology
Health
Biotechnology
Advertising and Marketing
Medical
Pharmaceutical
Research And Development
Finance

MYGN News

Barron's15h

Myriad Genetics Stock Has an F.D.A. Issue

47
ReutersAug 14

Edited Transcript of MYGN earnings conference call or presentation 13-Aug-19 8:30pm GMT

20
MarketWatchAug 14

Myriad Genetics stock plummets 39% after lower-than-expected earnings, FDA questions

2,195

MYGN Earnings

$0.24
$0.32
$0.39
$0.47
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
$0.47 per share
Actual
$0.41 per share

More MYGN News

BenzingaAug 14

Myriad Genetics, Inc. - What Caused The Opening Gap In Myriad Genetics?

104
Barron'sAug 14

Myriad Genetics Stock Craters on Weak Earnings and FDA Scrutiny

559
CNBCAug 13

Stocks making the biggest moves after hours: RealReal, Tilray, and Myriad

1,282
BenzingaAug 13

Myriad Genetics Q4 Earnings Preview

144
BenzingaAug 1

Myriad Genetics, Inc., UnitedHealth Group Incorporated - Myriad Genetics Shares Jump to 9-Month On Insurance Coverage For GeneSight Test

3,468
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.